‘Socialized Research’ and ‘Privatized Profits’: California's Gene Therapy Research and Million Dollar Plus Treatments
By David Jensen,
The California Stem Cell Report
| 08. 09. 2021
“One and Done” — If Companies Actually Go to Market
Only eight days after the California stem cell agency approved its most recent award for its $60 million battle against sickle cell disease came a cautionary note from 3,000 miles away.
The note sounded financial misgivings regarding the proposed, gene-editing treatments that have been highly touted as a possible cure for sickle cell disease, an affliction that occurs predominantly among African-Americans and other minorities.
The concerns came from the 60-member Congressional Black Caucus. Million-dollar plus price tags were the main matter for the federal lawmakers. “We are troubled that access to these medicines is anything but guaranteed for the patients who would benefit most from them,” the lawmakers said in a letter to the head of the mammoth U.S. Department of Health and Human Services.
The timing of the July 28 letter appears merely coincidental to the approval on July 20 of an $8.4 million gene-therapy grant by the California Institute for Regenerative Medicine (CIRM), as the stem cell agency is officially known.
The caucus letter was not directed at CIRM, which is likely not even on the lawmakers’...
Related Articles
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...
